Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 10, 2023New England Journal of MedicineOpen Access

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

BEBarbara EichhorstCNCarsten Utoft NiemannAKArnon P. Kater

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Eichhorst et al. (2023) studied this question.

synapsesocial.com/papers/6a03c3cd94ec7ec37ca9cfcdhttps://doi.org/10.1056/nejmoa2213093
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1COVID-19 among fit patients with CLL treated with venetoclax-based combinations2020 · 46 citations
  2. 2Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial2012 · 455 citations
  3. 3Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions2019 · 874 citations
  4. 4Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab2022 · 158 citations
  5. 5A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study2015 · 247 citations